Protease inhibition increases the analgesic potency of peptide E

Neuropharmacology. 1985 Feb;24(2):173-5. doi: 10.1016/0028-3908(85)90177-7.

Abstract

Peptide E (PE), an opioid peptide from adrenal medulla, is known to possess very low analgesic potency when injected intracerebroventricularly in mice. The present study showed that PE analgesia was increased by co-injection with protease inhibitors (bacitracin and bestatin).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analgesics / pharmacology*
  • Animals
  • Bacitracin / pharmacology
  • Drug Synergism
  • Endorphins / antagonists & inhibitors*
  • Enkephalins*
  • Injections, Intraventricular
  • Leucine / analogs & derivatives
  • Leucine / pharmacology
  • Male
  • Mice
  • Peptides / pharmacology*
  • Protease Inhibitors / pharmacology*
  • beta-Endorphin

Substances

  • Analgesics
  • Endorphins
  • Enkephalins
  • Peptides
  • Protease Inhibitors
  • Bacitracin
  • beta-Endorphin
  • peptide E (adrenal medulla)
  • Leucine
  • ubenimex